UNSPSC 51371903: Dimepheptanol or methadol or racemethadol

This classification denotes an opioid receptor agonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NNB4I01PA7, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as dimepheptanol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Dimepheptanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07161MIG.

The term DIMEPHEPTANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). DIMEPHEPTANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.

UNSPSC 51371903 Dimepheptanol or methadol or racemethadol is a Commodity code that in recent state and local procurement activity covers opioid-replacement therapies and related pharmaceutical products procured by health departments, county health systems, and cooperative purchasing alliances to support medication-assisted treatment and community health initiatives. The code spans naloxone (an opioid antagonist commonly procured alongside opioid-management products), generic pharmaceuticals distributed through state health benefit programs, and associated drug-management systems. Issuing bodies range from county health departments and state health and human services commissions to multi-state cooperative purchasing organizations serving state agencies and local government facilities across multiple jurisdictions.

Recent activity includes Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026, soliciting generic multi-source pharmaceuticals and OTC products for distribution across state and local government facilities in Minnesota, Oregon, and other participating jurisdictions, with proposals due March 26, 2026. Procurement activity concentrates in Florida and the upper Midwest, with state-level health agencies and cooperative alliances driving multi-jurisdiction demand for standardized pharmaceutical supply chains and naloxone distribution networks.